Weekly Digest – July 2026 Weekly Digest – July 2026 10 July 2026: U.S. FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility The U.S. FDA has approved PADCEV plus KEYTRUDA as neoadjuvant […]
Weekly Digest – July 2026 Weekly Digest – July 2026 14 July 2026: SOTIO receives FDA Fast Track Designation for CDH17-targeting ADC SOT109 for CRC SOTIO has received U.S. FDA Fast Track Designation for SOT109, its CDH17-targeting antibody-drug conjugate, for […]
Weekly Digest – July 2026 Weekly Digest – July 2026 10 July 2026: Hansoh Pharma announces ARTEMIS-008 trial achieved primary OS endpoint in SCLC Hansoh Pharma announced that its B7-H3-targeted antibody-drug conjugate Risvutatug rezetecan met the primary endpoint of overall […]
Weekly Digest – July 2026 Weekly Digest – July 2026 15 July 2026: Kelun-Biotech’s phase 3 trial of Sac-TMT plus Pembrolizumab met the primary endpoint in 1L PD-L1-negative non-squamous NSCLC Kelun-Biotech announced that its TROP2-targeted antibody-drug conjugate Sacituzumab tirumotecan, in […]
Weekly Digest – July 2026 Weekly Digest – July 2026 13 July 2026: VERAXA Biotech and Ardigen collaborate to accelerate AI-enabled BiTAC pipeline development VERAXA Biotech has entered an AI-enabled drug discovery collaboration with Ardigen to accelerate the development of […]
Weekly Digest – July 2026 Weekly Digest – July 2026 15 July 2026: Protina partners with Onconic Therapeutics on next-generation cancer drugs Proteina and Onconic Therapeutics have entered a strategic collaboration to develop next-generation oncology therapies, combining Proteina’s antibody engineering […]
